{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T14:54:40Z","timestamp":1791644080829,"version":"4.3.4"},"reference-count":203,"publisher":"Bentham Science Publishers Ltd.","issue":"4","funder":[{"DOI":"10.13039\/501100007642","name":"PRIN","doi-asserted-by":"publisher","award":["2017S9KTNE_002"],"award-info":[{"award-number":["2017S9KTNE_002"]}],"id":[{"id":"10.13039\/501100007642","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CN"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>Psychiatric drugs have primacy for off-label prescribing. Among those, selective serotonin\nreuptake inhibitors (SSRIs) are highly versatile and, therefore, widely prescribed. Moreover,\nthey are commonly considered as having a better safety profile compared to other antidepressants.\nThus, when it comes to off-label prescribing, SSRIs rank among the top positions. In this review,\nwe present the state of the art of off-label applications of selective serotonin reuptake inhibitors,\nranging from migraine prophylaxis to SARS-CoV-2 antiviral properties. Research on SSRIs provided\nsignificant evidence in the treatment of premature ejaculation, both with the on-label dapoxetine\n30 mg and the off-label paroxetine 20 mg. However, other than a serotoninergic syndrome,\nserious conditions like increased bleeding rates, hyponatremia, hepatoxicity, and post-SSRIs sexual\ndysfunctions, are consistently more prominent when using such compounds. These insidious side\neffects might be frequently underestimated during common clinical practice, especially by nonpsychiatrists.\nThus, some points must be addressed when using SSRIs. Among these, a psychiatric\nevaluation before every administration that falls outside the regulatory agencies-approved guidelines\nhas to be considered mandatory. For these reasons, we aim with the present article to identify\nthe risks of inappropriate uses and to advocate the need to actively boost research encouraging future\nclinical trials on this topic.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1570159x19666210517150418","type":"journal-article","created":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T09:12:51Z","timestamp":1621329171000},"page":"693-712","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":80,"title":["Off-label Uses of Selective Serotonin Reuptake Inhibitors (SSRIs)"],"prefix":"10.2174","volume":"20","author":[{"given":"Tommaso B.","family":"Jannini","sequence":"first","affiliation":[{"name":"Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio D.","family":"Lorenzo","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy | IRCCS-Fondazione Santa Lucia,\nRome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Bianciardi","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Niolu","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Toscano","sequence":"additional","affiliation":[{"name":"Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy | Department of\nNeurology, Fatebenefratelli Hospital, Isola Tiberina, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Ciocca","sequence":"additional","affiliation":[{"name":"Department of Dynamic and Clinical Psychology,\nand Health Studies, Sapienza University of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuele A.","family":"Jannini","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome\nTor Vergata, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Siracusano","sequence":"additional","affiliation":[{"name":"Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1001\/archinte.166.9.1021","volume":"166","author":"Radley D.C.","year":"2006","unstructured":"Radley D.C.; Finkelstein S.N.; Stafford R.S.; Off-label prescribing among office-based physicians. Arch Intern Med 2006,166(9),1021-1026","journal-title":"Arch Intern Med"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/pds.2082","volume":"20","author":"Alexander G.C.","year":"2011","unstructured":"Alexander G.C.; Gallagher S.A.; Mascola A.; Moloney R.M.; Stafford R.S.; Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol Drug Saf 2011,20(2),177-184","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1001\/archinternmed.2012.340","volume":"172","author":"Eguale T.","year":"2012","unstructured":"Eguale T.; Buckeridge D.L.; Winslade N.E.; Benedetti A.; Hanley J.A.; Tamblyn R.; Drug, patient, and physician characteristics associated with off-label prescribing in primary care. Arch Intern Med 2012,172(10),781-788","journal-title":"Arch Intern Med"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1056\/NEJMp0802107","volume":"358","author":"Stafford R.S.","year":"2008","unstructured":"Stafford R.S.; Regulating off-label drug use--rethinking the role of the FDA. N Engl J Med 2008,358(14),1427-1429","journal-title":"N Engl J Med"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"e4185","DOI":"10.7759\/cureus.4185","volume":"11","author":"Faquih A.E.","year":"2019","unstructured":"Faquih A.E.; Memon R.I.; Hafeez H.; Zeshan M.; Naveed S.; A review of novel antidepressants: a guide for clinicians. Cureus 2019,11(3),e4185","journal-title":"Cureus"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/164_2018_172","volume":"250","author":"Lochmann D.","year":"2019","unstructured":"Lochmann D.; Richardson T.; Selective serotonin reuptake inhibitors. Handb Exp Pharmacol 2019,250,135-144","journal-title":"Handb Exp Pharmacol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/GRF.0000000000000339","volume":"61","author":"Appleton S.M.","year":"2018","unstructured":"Appleton S.M.; Premenstrual Syndrome: Evidence-based evaluation and treatment. Clin Obstet Gynecol 2018,61(1),52-61","journal-title":"Clin Obstet Gynecol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1007\/s00228-013-1567-8","volume":"69","author":"Poluzzi E.","year":"2013","unstructured":"Poluzzi E.; Piccinni C.; Sangiorgi E.; Clo M.; Tarricone I.; Menchetti M.; De Ponti F.; Trend in SSRI-SNRI antidepressants prescription over a 6-year period and predictors of poor adherence. Eur J Clin Pharmacol 2013,69(12),2095-2101","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"j603","DOI":"10.1136\/bmj.j603","volume":"356","author":"Wong J.","year":"2017","unstructured":"Wong J.; Motulsky A.; Abrahamowicz M.; Eguale T.; Buckeridge D.L.; Tamblyn R.; Off-label indications for antidepressants in primary care: descriptive study of prescriptions from an indication based electronic prescribing system. BMJ 2017,356,j603","journal-title":"BMJ"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.clinthera.2014.06.001","volume":"36","author":"Qin B.","year":"2014","unstructured":"Qin B.; Selective serotonin reuptake inhibitors versus tricyclic antidepressants in young patients: A meta-analysis of efficacy and acceptability. Clin Ther 2014,36(7),1087-1095","journal-title":"Clin Ther"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12916-018-1022-x","volume":"16","author":"Coupland C.","year":"2018","unstructured":"Coupland C.; Hill T.; Morriss R.; Moore M.; Arthur A.; Hippisley-Cox J.; Antidepressant use and risk of adverse outcomes in people aged 20-64 years: cohort study using a primary care database. BMC Med 2018,16(1),36","journal-title":"BMC Med"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1080\/09540260801889211","volume":"20","author":"Murphy T.K.","year":"2008","unstructured":"Murphy T.K.; Segarra A.; Storch E.A.; Goodman W.K.; SSRI adverse events: how to monitor and manage. Int Rev Psychiatry 2008,20(2),203-208","journal-title":"Int Rev Psychiatry"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"e773","DOI":"10.3399\/bjgp12X658304","volume":"62","author":"Johnson C.F.","year":"2012","unstructured":"Johnson C.F.; Macdonald H.J.; Atkinson P.; Buchanan A.I.; Downes N.; Dougall N.; Reviewing long-term antidepressants can reduce drug burden: a prospective observational cohort study. Br J Gen Pract 2012,62(604),e773-e779","journal-title":"Br J Gen Pract"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/ageing\/afl023","volume":"35","author":"Petty D.R.","year":"2006","unstructured":"Petty D.R.; House A.; Knapp P.; Raynor T.; Zermansky A.; Prevalence, duration and indications for prescribing of antidepressants in primary care. Age Ageing 2006,35(5),523-526","journal-title":"Age Ageing"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"b3999","DOI":"10.1136\/bmj.b3999","volume":"339","author":"Moore M.","year":"2009","unstructured":"Moore M.; Yuen H.M.; Dunn N.; Mullee M.A.; Maskell J.; Kendrick T.; Explaining the rise in antidepressant prescribing: a descriptive study using the general practice research database. BMJ 2009,339,b3999","journal-title":"BMJ"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12875-017-0643-z","volume":"18","author":"Johnson C.F.","year":"2017","unstructured":"Johnson C.F.; Williams B.; MacGillivray S.A.; Dougall N.J.; Maxwell M.; \u2018Doing the right thing\u2019: factors influencing GP prescribing of antidepressants and prescribed doses. BMC Fam Pract 2017,18(1),72","journal-title":"BMC Fam Pract"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/j.1526-4610.1992.hed3202101.x","volume":"32","author":"Adly C.","year":"1992","unstructured":"Adly C.; Straumanis J.; Chesson A.; Fluoxetine prophylaxis of migraine. Headache 1992,32(2),101-104","journal-title":"Headache"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/j.1526-4610.1994.hed3408476.x","volume":"34","author":"B\u00e1nk J.","year":"1994","unstructured":"B\u00e1nk J.; A comparative study of amitriptyline and fluvoxamine in migraine prophylaxis. Headache 1994,34(8),476-478","journal-title":"Headache"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1046\/j.1526-4610.1999.3910716.x","volume":"39","author":"d\u2019Amato C.C.","year":"1999","unstructured":"d\u2019Amato C.C.; Pizza V.; Marmolo T.; Giordano E.; Alfano V.; Nasta A.; Fluoxetine for migraine prophylaxis: a double-blind trial. Headache 1999,39(10),716-719","journal-title":"Headache"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1046\/j.1526-4610.2002.02125.x","volume":"42","author":"Krymchantowski A.V.","year":"2002","unstructured":"Krymchantowski A.V.; Silva M.T.; Barbosa J.S.; Alves L.A.; Amitriptyline versus amitriptyline combined with fluoxetine in the preventative treatment of transformed migraine: a double-blind study. Headache 2002,42(6),510-514","journal-title":"Headache"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1046\/j.1526-4610.1999.3901028.x","volume":"39","author":"Landy S.","year":"1999","unstructured":"Landy S.; McGinnis J.; Curlin D.; Laizure S.C.; Selective serotonin reuptake inhibitors for migraine prophylaxis. Headache 1999,39(1),28-32","journal-title":"Headache"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1046\/j.1468-2982.1998.1805283.x","volume":"18","author":"Steiner T.J.","year":"1998","unstructured":"Steiner T.J.; Ahmed F.; Findley L.J.; MacGregor E.A.; Wilkinson M.; S-fluoxetine in the prophylaxis of migraine: a phase II double-blind randomized placebo-controlled study. Cephalalgia 1998,18(5),283-286","journal-title":"Cephalalgia"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/WNF.0b013e3181a8c84f","volume":"32","author":"Tarlaci S.","year":"2009","unstructured":"Tarlaci S.; Escitalopram and venlafaxine for the prophylaxis of migraine headache without mood disorders. Clin Neuropharmacol 2009,32(5),254-258","journal-title":"Clin Neuropharmacol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1001\/archpsyc.56.11.1033","volume":"56","author":"Hollander E.","year":"1999","unstructured":"Hollander E.; Allen A.; Kwon J.; Aronowitz B.; Schmeidler J.; Wong C.; Simeon D.; Clomipramine vs desipramine crossover trial in body dysmorphic disorder: selective efficacy of a serotonin reuptake inhibitor in imagined ugliness. Arch Gen Psychiatry 1999,56(11),1033-1039","journal-title":"Arch Gen Psychiatry"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/00004850-199612000-00006","volume":"11","author":"Perugi G.","year":"1996","unstructured":"Perugi G.; Giannotti D.; Di Vaio S.; Frare F.; Saettoni M.; Cassano G.B.; Fluvoxamine in the treatment of body dysmorphic disorder (dysmorphophobia). Int Clin Psychopharmacol 1996,11(4),247-254","journal-title":"Int Clin Psychopharmacol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/01.yic.0000194378.65460.ef","volume":"21","author":"Phillips K.A.","year":"2006","unstructured":"Phillips K.A.; An open-label study of escitalopram in body dysmorphic disorder. Int Clin Psychopharmacol 2006,21(3),177-179","journal-title":"Int Clin Psychopharmacol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"715","DOI":"10.4088\/JCP.v64n0615","volume":"64","author":"Phillips K.A.","year":"2003","unstructured":"Phillips K.A.; Najjar F.; An open-label study of citalopram in body dysmorphic disorder. J Clin Psychiatry 2003,64(6),715-720","journal-title":"J Clin Psychiatry"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1001\/archpsyc.59.4.381","volume":"59","author":"Phillips K.A.","year":"2002","unstructured":"Phillips K.A.; Albertini R.S.; Rasmussen S.A.; A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder. Arch Gen Psychiatry 2002,59(4),381-388","journal-title":"Arch Gen Psychiatry"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1176\/appi.ajp.2016.15091243","volume":"173","author":"Phillips K.A.","year":"2016","unstructured":"Phillips K.A.; Keshaviah A.; Dougherty D.D.; Stout R.L.; Menard W.; Wilhelm S.; Pharmacotherapy relapse prevention in body dysmorphic disorder: a double-blind, placebo-controlled trial. Am J Psychiatry 2016,173(9),887-895","journal-title":"Am J Psychiatry"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"165","DOI":"10.4088\/JCP.v59n0404","volume":"59","author":"Phillips K.A.","year":"1998","unstructured":"Phillips K.A.; Dwight M.M.; McElroy S.L.; Efficacy and safety of fluvoxamine in body dysmorphic disorder. J Clin Psychiatry 1998,59(4),165-171","journal-title":"J Clin Psychiatry"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1111\/jgh.14375","volume":"34","author":"Stasi C.","year":"2019","unstructured":"Stasi C.; Caserta A.; Nisita C.; Cortopassi S.; Fani B.; Salvadori S.; Pancetti A.; Bertani L.; Gambaccini D.; de Bortoli N.; Dell\u2019Osso L.; Blandizzi C.; Marchi S.; Bellini M.; The complex interplay between gastrointestinal and psychiatric symptoms in irritable bowel syndrome: A longitudinal assessment. J Gastroenterol Hepatol 2019,34(4),713-719","journal-title":"J Gastroenterol Hepatol"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.aimed.2019.01.001","volume":"6","author":"Tadyon N.B.","year":"2019","unstructured":"Tadyon N.B.; Therapeutic effects of saffron (Crocus sativus) versus fluoxetine on Irritable Bowel Syndrome: A double-blind randomized clinical trial. Adv Integr Med 2019,6(4),167-173","journal-title":"Adv Integr Med"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"12829","DOI":"10.1111\/and.12829","volume":"50","author":"Abu El-Hamd M.","year":"2018","unstructured":"Abu El-Hamd M.; Abdelhamed A.; Comparison of the clinical efficacy and safety of the on-demand use of paroxetine, dapoxetine, sildenafil and combined dapoxetine with sildenafil in treatment of patients with premature ejaculation: A randomised placebo-controlled clinical trial. Andrologia 2018,50(1),12829","journal-title":"Andrologia"},{"key":"ref=34","first-page":"41","volume":"5","author":"Akg\u00fcl T.","year":"2008","unstructured":"Akg\u00fcl T.; Karakan T.; Ayyildiz A.; Germiyano\u011flu C.; Comparison of sertraline and citalopram for treatment of premature ejaculation. Urol J 2008,5(1),41-45","journal-title":"Urol J"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/sj.ijir.3900918","volume":"14","author":"Atmaca M.","year":"2002","unstructured":"Atmaca M.; Kuloglu M.; Tezcan E.; Semercioz A.; The efficacy of citalopram in the treatment of premature ejaculation: a placebo-controlled study. Int J Impot Res 2002,14(6),502-505","journal-title":"Int J Impot Res"},{"key":"ref=36","first-page":"185","volume":"72","author":"Balci M.","year":"2019","unstructured":"Balci M.; Atan A.; Senel C.; Guzel O.; Aslan Y.; Lokman U.; Kayali M.; Bilgin O.; Comparison of the treatment efficacies of paroxetine, fluoxetine and dapoxetine in low socioeconomic status patients with lifelong premature ejaculation. Cent Eur J Urol 2019,72(2),185-190","journal-title":"Cent Eur J Urol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.aju.2013.05.003","volume":"11","author":"Gameel T.A.","year":"2013","unstructured":"Gameel T.A.; Tawfik A.M.; Abou-Farha M.O.; Bastawisy M.G.; El-Bendary M.A.; El-Gamasy, Ael-N. On-demand use of tramadol, sildenafil, paroxetine and local anaesthetics for the management of premature ejaculation: A randomised placebo-controlled clinical trial. Arab J Urol 2013,11(4),392-397","journal-title":"Arab J Urol"},{"key":"ref=38","first-page":"923","volume":"17","author":"Gong Z.Y.","year":"2011","unstructured":"Gong Z.Y.; Tang T.L.; Cui S.; Wang J.Z.; Deng X.Z.; Oral paroxetine for premature ejaculation: a randomized controlled study. Zhonghua Nan Ke Xue 2011,17(10),923-925","journal-title":"Zhonghua Nan Ke Xue"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1097\/00004714-199802000-00012","volume":"18","author":"Haensel S.M.","year":"1998","unstructured":"Haensel S.M.; Klem T.M.; Hop W.C.; Slob A.K.; Fluoxetine and premature ejaculation: a double-blind, crossover, placebo-controlled study. J Clin Psychopharmacol 1998,18(1),72-77","journal-title":"J Clin Psychopharmacol"},{"key":"ref=40","first-page":"10","volume":"19","author":"Hamidi-Madani A.","year":"2018","unstructured":"Hamidi-Madani A.; Motiee R.; Mokhtari G.; Nasseh H.; Esmaeili S.; Kazemnezhad E.; The efficacy and safety of on-demand tramadol and paroxetine use in treatment of life long premature ejaculation: A randomized double-blind placebo-controlled clinical trial. J Reprod Infertil 2018,19(1),10-15","journal-title":"J Reprod Infertil"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1159\/000102909","volume":"79","author":"Hosseini M.M.","year":"2007","unstructured":"Hosseini M.M.; Yarmohammadi H.; Effect of fluoxetine alone and in combination with sildenafil in patients with premature ejaculation. Urol Int 2007,79(1),28-32","journal-title":"Urol Int"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1016\/j.jsxm.2019.09.017","volume":"16","author":"Jenkins L.C.","year":"2019","unstructured":"Jenkins L.C.; Gonzalez J.; Tal R.; Guhring P.; Parker M.; Mulhall J.P.; Compliance with fluoxetine use in men with primary premature ejaculation. J Sex Med 2019,16(12),1895-1899","journal-title":"J Sex Med"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1016\/S0022-5347(01)65467-3","volume":"156","author":"Kara H.","year":"1996","unstructured":"Kara H.; Aydin S.; Y\u00fccel M.; Agarg\u00fcn M.Y.; Odaba\u015f O.; Yilmaz Y.; The efficacy of fluoxetine in the treatment of premature ejaculation: a double-blind placebo controlled study. J Urol 1996,156(5),1631-1632","journal-title":"J Urol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S0022-5347(01)63940-5","volume":"159","author":"Kim S.C.","year":"1998","unstructured":"Kim S.C.; Seo K.K.; Efficacy and safety of fluoxetine, sertraline and clomipramine in patients with premature ejaculation: a double-blind, placebo controlled study. J Urol 1998,159(2),425-427","journal-title":"J Urol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1111\/j.1743-6109.2008.00843.x","volume":"5","author":"Madeo B.","year":"2008","unstructured":"Madeo B.; Bettica P.; Milleri S.; Balestrieri A.; Granata A.R.; Carani C.; Rochira V.; The effects of citalopram and fluoxetine on sexual behavior in healthy men: evidence of delayed ejaculation and unaffected sexual desire. A randomized, placebo-controlled, double-blind, double-dummy, parallel group study. J Sex Med 2008,5(10),2431-2441","journal-title":"J Sex Med"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1097\/01.ju.0000071040.12407.32","volume":"170","author":"Manasia P.","year":"2003","unstructured":"Manasia P.; Pomerol J.; Rib\u00e8 N.; Gutierrez del Pozo R.; Alcover Garcia J.; Comparison of the efficacy and safety of 90 mg versus 20 mg fluoxetine in the treatment of premature ejaculation. J Urol 2003,170(1),164-165","journal-title":"J Urol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1159\/000112607","volume":"80","author":"Mattos R.M.","year":"2008","unstructured":"Mattos R.M.; Marmo Lucon A.; Srougi M.; Tadalafil and fluoxetine in premature ejaculation: prospective, randomized, double-blind, placebo-controlled study. Urol Int 2008,80(2),162-165","journal-title":"Urol Int"},{"key":"ref=48","first-page":"261","volume":"9","author":"Nada E.A.","year":"2012","unstructured":"Nada E.A.; A Comparison between citalopram and escitalopram in treatment of patients with premature ejaculation: a double-blind controlled clinical study. J Sex Med 2012,9,261-262","journal-title":"J Sex Med"},{"key":"ref=49","first-page":"6","author":"Nada E.","year":"2009","unstructured":"Nada E.; Saleh R.; Abu M.; The use of Escitalopram in treatment of patients with premature ejaculation: A randomized, double-blind, placebo-controlled study. J Sex Med 2009,6","journal-title":"J Sex Med"},{"key":"ref=50","first-page":"116","volume":"28","author":"Novaretti J.P.T.","year":"2002","unstructured":"Novaretti J.P.T.; Pompeo A.; Arap S.; Selective serotonin re-uptake inhibitor in the treatment of premature ejaculation. Br J Urol 2002,28(2),116-122","journal-title":"Br J Urol"},{"key":"ref=51","first-page":"55","volume":"8","author":"Rezakhaniha B.","year":"2010","unstructured":"Rezakhaniha B.; Sirosbakht S.; Efficacy of selective serotonin reuptake inhibitor (SSRI) in patient with premature ejaculation. Iran J Reprod Med 2010,8(2),55-59","journal-title":"Iran J Reprod Med"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/01.WNF.0000228210.12194.46","volume":"29","author":"Safarinejad M.R.","year":"2006","unstructured":"Safarinejad M.R.; Comparison of dapoxetine versus paroxetine in patients with premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Clin Neuropharmacol 2006,29(5),243-252","journal-title":"Clin Neuropharmacol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1097\/jcp.0b013e31814b98d4","volume":"27","author":"Safarinejad M.R.","year":"2007","unstructured":"Safarinejad M.R.; Safety and efficacy of escitalopram in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. J Clin Psychopharmacol 2007,27(5),444-450","journal-title":"J Clin Psychopharmacol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/sj.ijir.3901384","volume":"18","author":"Safarinejad M.R.","year":"2006","unstructured":"Safarinejad M.R.; Hosseini S.Y.; Safety and efficacy of citalopram in the treatment of premature ejaculation: a double-blind placebo-controlled, fixed dose, randomized study. Int J Impot Res 2006,18(2),164-169","journal-title":"Int J Impot Res"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.eururo.2011.01.019","volume":"59","author":"Sunay D.","year":"2011","unstructured":"Sunay D.; Sunay M.; Aydo\u011fmu\u015f Y.; Ba\u011fbanc\u0131 S.; Arslan H.; Karabulut A.; Emir L.; Acupuncture versus paroxetine for the treatment of premature ejaculation: a randomized, placebo-controlled clinical trial. Eur Urol 2011,59(5),765-771","journal-title":"Eur Urol"},{"key":"ref=56","first-page":"353","volume":"47","author":"Vahid F.","year":"2009","unstructured":"Vahid F.; On-demand treatment of premature ejaculation with citalopram: A Randomized double-blind study. Acta Med Iran 2009,47(5),353-357","journal-title":"Acta Med Iran"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1097\/00004714-199808000-00004","volume":"18","author":"Waldinger M.D.","year":"1998","unstructured":"Waldinger M.D.; Hengeveld M.W.; Zwinderman A.H.; Olivier B.; Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. J Clin Psychopharmacol 1998,18(4),274-281","journal-title":"J Clin Psychopharmacol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1097\/00004714-200106000-00007","volume":"21","author":"Waldinger M.D.","year":"2001","unstructured":"Waldinger M.D.; Zwinderman A.H.; Olivier B.; Antidepressants and ejaculation: a double-blind, randomized, placebo-controlled, fixed-dose study with paroxetine, sertraline, and nefazodone. J Clin Psychopharmacol 2001,21(3),293-297","journal-title":"J Clin Psychopharmacol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S0022-5347(01)62078-0","volume":"161","author":"Yilmaz U.","year":"1999","unstructured":"Yilmaz U.; Tatli\u015fen A.; Turan H.; Arman F.; Ekmek\u00e7io\u011flu O.; The effects of fluoxetine on several neurophysiological variables in patients with premature ejaculation. J Urol 1999,161(1),107-111","journal-title":"J Urol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1300\/J076v18n03_08","volume":"18","author":"Coleman E.","year":"1992","unstructured":"Coleman E.; An exploratory study of the role of psychotropic medications in the treatment of sex offenders. J Offender Rehabil 1992,18(3-4),75-88","journal-title":"J Offender Rehabil"},{"key":"ref=61","first-page":"525","volume":"24","author":"Greenberg D.M.","year":"1996","unstructured":"Greenberg D.M.; Bradford J.M.; Curry S.; O\u2019Rourke A.; A comparison of treatment of paraphilias with three serotonin reuptake inhibitors: a retrospective study. Bull Am Acad Psychiatry Law 1996,24(4),525-532","journal-title":"Bull Am Acad Psychiatry Law"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3109\/10401239409149003","volume":"6","author":"Kafka M.P.","year":"1994","unstructured":"Kafka M.P.; Sertraline pharmacotherapy for paraphilias and paraphilia-related disorders: an open trial. Ann Clin Psychiatry 1994,6(3),189-195","journal-title":"Ann Clin Psychiatry"},{"key":"ref=63","first-page":"60","volume":"52","author":"Kafka M.P.","year":"1991","unstructured":"Kafka M.P.; Successful antidepressant treatment of nonparaphilic sexual addictions and paraphilias in men. J Clin Psychiatry 1991,52(2),60-65","journal-title":"J Clin Psychiatry"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"664","DOI":"10.4088\/JCP.v61n0912","volume":"61","author":"Kafka M.P.","year":"2000","unstructured":"Kafka M.P.; Hennen J.; Psychostimulant augmentation during treatment with selective serotonin reuptake inhibitors in men with paraphilias and paraphilia-related disorders: a case series. J Clin Psychiatry 2000,61(9),664-670","journal-title":"J Clin Psychiatry"},{"key":"ref=65","first-page":"345","volume":"53","author":"Kafka M.P.","year":"1992","unstructured":"Kafka M.P.; Prentky R.; A comparative study of nonparaphilic sexual addictions and paraphilias in men. J Clin Psychiatry 1992,53(10),345-350","journal-title":"J Clin Psychiatry"},{"key":"ref=66","first-page":"351","volume":"53","author":"Kafka M.P.","year":"1992","unstructured":"Kafka M.P.; Prentky R.; Fluoxetine treatment of nonparaphilic sexual addictions and paraphilias in men. J Clin Psychiatry 1992,53(10),351-358","journal-title":"J Clin Psychiatry"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1055\/s-2006-944261","volume":"75","author":"Kraus C.","year":"2007","unstructured":"Kraus C.; Strohm K.; Hill A.; Habermann N.; Berner W.; Briken P.; Selective serotonine reuptake inhibitors (SSRI) in the treatment of paraphilia. Fortschr Neurol Psychiatr 2007,75(6),351-356","journal-title":"Fortschr Neurol Psychiatr"},{"key":"ref=68","first-page":"267","volume":"53","author":"Stein D.J.","year":"1992","unstructured":"Stein D.J.; Hollander E.; Anthony D.T.; Schneier F.R.; Fallon B.A.; Liebowitz M.R.; Klein D.F.; Serotonergic medications for sexual obsessions, sexual addictions, and paraphilias. J Clin Psychiatry 1992,53(8),267-271","journal-title":"J Clin Psychiatry"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.maturitas.2012.09.006","volume":"73","author":"LaCroix A.Z.","year":"2012","unstructured":"LaCroix A.Z.; Freeman E.W.; Larson J.; Carpenter J.S.; Joffe H.; Reed S.D.; Newton K.M.; Seguin R.A.; Sternfeld B.; Cohen L.; Ensrud K.E.; Effects of escitalopram on menopause-specific quality of life and pain in healthy menopausal women with hot flashes: a randomized controlled trial. Maturitas 2012,73(4),361-368","journal-title":"Maturitas"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1200\/JCO.2009.26.6379","volume":"28","author":"Barton D.L.","year":"2010","unstructured":"Barton D.L.; LaVasseur B.I.; Sloan J.A.; Stawis A.N.; Flynn K.A.; Dyar M.; Johnson D.B.; Atherton P.J.; Diekmann B.; Loprinzi C.L.; Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9. J Clin Oncol 2010,28(20),3278-3283","journal-title":"J Clin Oncol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/europace\/euw153","volume":"19","author":"Flevari P.","year":"2017","unstructured":"Flevari P.; Leftheriotis D.; Repasos E.; Katsaras D.; Katsimardos A.; Lekakis J.; Fluoxetine vs. placebo for the treatment of recurrent vasovagal syncope with anxiety sensitivity. Europace 2017,19(1),127-131","journal-title":"Europace"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"e339","DOI":"10.1097\/MJT.0000000000000652","volume":"26","author":"Kadri A.N.","year":"2019","unstructured":"Kadri A.N.; Nusairat L.; Kadri S.; Alqaid A.; Hernandez A.V.; Kadri N.N.; Effect of citalopram for the treatment of neurocardiogenic syncope. Am J Ther 2019,26(3),e339-e343","journal-title":"Am J Ther"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1001\/archpsyc.1997.01830240035005","volume":"54","author":"Coccaro E.F.","year":"1997","unstructured":"Coccaro E.F.; Kavoussi R.J.; Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Arch Gen Psychiatry 1997,54(12),1081-1088","journal-title":"Arch Gen Psychiatry"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/S0006-3223(97)00309-0","volume":"42","author":"Coccaro E.F.","year":"1997","unstructured":"Coccaro E.F.; Kavoussi R.J.; Hauger R.L.; Serotonin function and antiaggressive response to fluoxetine: a pilot study. Biol Psychiatry 1997,42(7),546-552","journal-title":"Biol Psychiatry"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"653","DOI":"10.4088\/JCP.08m04150","volume":"70","author":"Coccaro E.F.","year":"2009","unstructured":"Coccaro E.F.; Lee R.J.; Kavoussi R.J.; A double-blind, randomized, placebo-controlled trial of fluoxetine in patients with intermittent explosive disorder. J Clin Psychiatry 2009,70(5),653-662","journal-title":"J Clin Psychiatry"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"60","DOI":"10.4088\/JCP.09m05256gry","volume":"72","author":"George D.T.","year":"2011","unstructured":"George D.T.; Phillips M.J.; Lifshitz M.; Lionetti T.A.; Spero D.E.; Ghassemzedeh N.; Doty L.; Umhau J.C.; Rawlings R.R.; Fluoxetine treatment of alcoholic perpetrators of domestic violence: a 12-week, double-blind, randomized, placebo-controlled intervention study. J Clin Psychiatry 2011,72(1),60-65","journal-title":"J Clin Psychiatry"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"422","DOI":"10.4088\/JCP.v68n0311","volume":"68","author":"Koran L.M.","year":"2007","unstructured":"Koran L.M.; Aboujaoude E.N.; Gamel N.N.; Escitalopram treatment of kleptomania: an open-label trial followed by double-blind discontinuation. J Clin Psychiatry 2007,68(3),422-427","journal-title":"J Clin Psychiatry"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1097\/YIC.0b013e32830fbdd2","volume":"23","author":"Lee R.","year":"2008","unstructured":"Lee R.; Kavoussi R.J.; Coccaro E.F.; Placebo-controlled, randomized trial of fluoxetine in the treatment of aggression in male intimate partner abusers. Int Clin Psychopharmacol 2008,23(6),337-341","journal-title":"Int Clin Psychopharmacol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"81","DOI":"10.4088\/JCP.v64n0115","volume":"64","author":"Reist C.","year":"2003","unstructured":"Reist C.; Nakamura K.; Sagart E.; Sokolski K.N.; Fujimoto K.A.; Impulsive aggressive behavior: open-label treatment with citalopram. J Clin Psychiatry 2003,64(1),81-85","journal-title":"J Clin Psychiatry"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/j.1600-0447.1995.tb09793.x","volume":"91","author":"Vartiainen H.","year":"1995","unstructured":"Vartiainen H.; Tiihonen J.; Putkonen A.; Koponen H.; Virkkunen M.; Hakola P.; Lehto H.; Citalopram, a selective serotonin reuptake inhibitor, in the treatment of aggression in schizophrenia. Acta Psychiatr Scand 1995,91(5),348-351","journal-title":"Acta Psychiatr Scand"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"2020915","DOI":"10.1155\/2016\/2020915","volume":"2016","author":"Patetsos E.","year":"2016","unstructured":"Patetsos E.; Horjales-Araujo E.; Treating Chronic Pain with SSRIs: What Do We Know? Pain Res Manag 2016,2016,2020915","journal-title":"Pain Res Manag"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s11940-019-0557-2","volume":"21","author":"Burch R.","year":"2019","unstructured":"Burch R.; Antidepressants for preventive treatment of migraine. Curr Treat Options Neurol 2019,21(4),18","journal-title":"Curr Treat Options Neurol"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"365","DOI":"10.2147\/CEG.S146646","volume":"11","author":"Bonilla S.","year":"2018","unstructured":"Bonilla S.; Nurko S.; Focus on the use of antidepressants to treat pediatric functional abdominal pain: current perspectives. Clin Exp Gastroenterol 2018,11,365-372","journal-title":"Clin Exp Gastroenterol"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.pharep.2017.05.014","volume":"69","author":"Ku\u0142ak-Bejda A.","year":"2017","unstructured":"Ku\u0142ak-Bejda A.; Bejda G.; Waszkiewicz N.; Antidepressants for irritable bowel syndrome-A systematic review. Pharmacol Rep 2017,69(6),1366-1379","journal-title":"Pharmacol Rep"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"4225","DOI":"10.12659\/MSM.913606","volume":"25","author":"Du Y.","year":"2019","unstructured":"Du Y.; Jiang Y.; Zhang J.; Tian G.; Zhang N.; Wu D.; Bai X.; Efficacy and Safety of \u201cOn-Demand\u201d dapoxetine in treatment of patients with premature ejaculation: A Meta-Analysis. Med Sci Monit 2019,25,4225-4232","journal-title":"Med Sci Monit"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1007\/s11255-018-1984-9","volume":"50","author":"Jian Z.","year":"2018","unstructured":"Jian Z.; Wei X.; Ye D.; Li H.; Wang K.; Pharmacotherapy of premature ejaculation: a systematic review and network meta-analysis. Int Urol Nephrol 2018,50(11),1939-1948","journal-title":"Int Urol Nephrol"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"e15989","DOI":"10.1097\/MD.0000000000015989","volume":"98","author":"Yi Z.M.","year":"2019","unstructured":"Yi Z.M.; Chen S.D.; Tang Q.Y.; Tang H.L.; Zhai S.D.; Efficacy and safety of sertraline for the treatment of premature ejaculation: Systematic review and meta-analysis. Medicine (Baltimore) 2019,98(23),e15989","journal-title":"Medicine (Baltimore)"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12894-018-0431-7","volume":"19","author":"Zhang D.","year":"2019","unstructured":"Zhang D.; Cheng Y.; Wu K.; Ma Q.; Jiang J.; Yan Z.; Paroxetine in the treatment of premature ejaculation: a systematic review and meta-analysis. BMC Urol 2019,19(1),2","journal-title":"BMC Urol"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"E554","DOI":"10.3390\/medicina55090554","volume":"55","author":"Riemma G.","year":"2019","unstructured":"Riemma G.; Schiattarella A.; La Verde M.; Zarobbi G.; Garzon S.; Cucinella G.; Calagna G.; Labriola D.; De Franciscis P.; Efficacy of low-dose paroxetine for the treatment of hot flushes in surgical and physiological postmenopausal women: systematic review and meta-analysis of randomized trials. Medicina (Kaunas) 2019,55(9),E554","journal-title":"Medicina (Kaunas)"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s11325-019-01954-9","volume":"24","author":"Abdel F.M.R.","year":"2020","unstructured":"Abdel F.M.R.; Jung S.W.; Greenspan M.A.; Padilla M.; Enciso R.; Efficacy of antidepressants in the treatment of obstructive sleep apnea compared to placebo. a systematic review with meta-analysis. Sleep Breath 2020,24(2),443-453","journal-title":"Sleep Breath"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"CD009286","DOI":"10.1002\/14651858.CD009286.pub3","volume":"2019","author":"Legg L.A.","year":"2019","unstructured":"Legg L.A.; Tilney R.; Hsieh C.F.; Wu S.; Lundstr\u00f6m E.; Rudberg A.S.; Kutlubaev M.A.; Dennis M.; Soleimani B.; Barugh A.; Hackett M.L.; Hankey G.J.; Mead G.E.; Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database Syst Rev 2019,2019(11),CD009286","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1556\/2006.5.2016.064","volume":"5","author":"Hague B.","year":"2016","unstructured":"Hague B.; Hall J.; Kellett S.; Treatments for compulsive buying: A systematic review of the quality, effectiveness and progression of the outcome evidence. J Behav Addict 2016,5(3),379-394","journal-title":"J Behav Addict"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S0140-6736(15)60692-4","volume":"386","author":"Vos T.","year":"2015","unstructured":"Vos T.; Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015,386(9995),743-800","journal-title":"Lancet"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.ncl.2019.06.001","volume":"37","author":"Burch R.C.","year":"2019","unstructured":"Burch R.C.; Buse D.C.; Lipton R.B.; Migraine: epidemiology, burden, and comorbidity. Neurol Clin 2019,37(4),631-649","journal-title":"Neurol Clin"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1056\/NEJMc1711803","volume":"377","author":"Charles A.","year":"2017","unstructured":"Charles A.; Migraine. N Engl J Med 2017,377(17),1698-1699","journal-title":"N Engl J Med"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"E3527","DOI":"10.3390\/ijms20143527","volume":"20","author":"Huang I.H.","year":"2019","unstructured":"Huang I.H.; Wu P.C.; Lin E.Y.; Chen C.Y.; Kang Y.N.; Effects of anti-calcitonin gene-related peptide for migraines: a systematic review with meta-analysis of randomized clinical trials. Int J Mol Sci 2019,20(14),E3527","journal-title":"Int J Mol Sci"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s10194-018-0901-z","volume":"19","author":"Vigan\u00f2 A.","year":"2018","unstructured":"Vigan\u00f2 A.; Torrieri M.C.; Toscano M.; Puledda F.; Petolicchio B.; Sasso D\u2019Elia T.; Verzina A.; Ruggiero S.; Altieri M.; Vicenzini E.; Schoenen J.; Di Piero V.; Neurophysiological correlates of clinical improvement after greater occipital nerve (GON) block in chronic migraine: relevance for chronic migraine pathophysiology. J Headache Pain 2018,19(1),73","journal-title":"J Headache Pain"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3389\/fphar.2019.00032","volume":"10","author":"Vigan\u00f2 A.","year":"2019","unstructured":"Vigan\u00f2 A.; Toscano M.; Puledda F.; Di Piero V.; Treating chronic migraine with neuromodulation: the role of neurophysiological abnormalities and maladaptive plasticity. Front Pharmacol 2019,10,32","journal-title":"Front Pharmacol"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1177\/0333102416640501","volume":"37","author":"Deen M.","year":"2017","unstructured":"Deen M.; Christensen C.E.; Hougaard A.; Hansen H.D.; Knudsen G.M.; Ashina M.; Serotonergic mechanisms in the migraine brain - a systematic review. Cephalalgia 2017,37(3),251-264","journal-title":"Cephalalgia"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"640574","DOI":"10.3389\/fnhum.2021.640574","volume":"15","author":"Altamura C.","year":"2021","unstructured":"Altamura C.; Corbelli I.; de Tommaso M.; Di Lorenzo C.; Di Lorenzo G.; Di Renzo A.; Filippi M.; Jannini T.B.; Messina R.; Parisi P.; Parisi V.; Pierelli F.; Rainero I.; Raucci U.; Rubino E.; Sarchielli P.; Li L.; Vernieri F.; Vollono C.; Coppola G.; Pathophysiological bases of comorbidity in migraine. Front Hum Neurosci 2021,15(131),640574","journal-title":"Front Hum Neurosci"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/j.1526-4610.1994.hed3409497.x","volume":"34","author":"Saper J.R.","year":"1994","unstructured":"Saper J.R.; Silberstein S.D.; Lake A.E.; Winters M.E.; Double-blind trial of fluoxetine: chronic daily headache and migraine. Headache 1994,34(9),497-502","journal-title":"Headache"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.1526-4610.1995.hed3504233_1.x","volume":"35","author":"Saper J.R.","year":"1995","unstructured":"Saper J.R.; Silberstein S.D.; Lake A.E.; Winters M.E.; Fluoxetine and migraine: comparison of double-blind trials. Headache 1995,35(4),233","journal-title":"Headache"},{"key":"ref=103","first-page":"330","volume":"56","author":"Black K.J.","year":"1995","unstructured":"Black K.J.; Sheline Y.I.; Paroxetine as migraine prophylaxis. J Clin Psychiatry 1995,56(7),330-331","journal-title":"J Clin Psychiatry"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"30","DOI":"10.4088\/JCP.v58n0106b","volume":"58","author":"Hays P.","year":"1997","unstructured":"Hays P.; Paroxetine prevents migraines. J Clin Psychiatry 1997,58(1),30-31","journal-title":"J Clin Psychiatry"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1212\/WNL.0b013e3182535d20","volume":"78","author":"Silberstein S.D.","year":"2012","unstructured":"Silberstein S.D.; Holland S.; Freitag F.; Dodick D.W.; Argoff C.; Ashman E.; Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012,78(17),1337-1345","journal-title":"Neurology"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1159\/000104469","volume":"55","author":"Alemdar M.","year":"2007","unstructured":"Alemdar M.; Selekler H.M.; Migraine with aura triggered by citalopram. Neuropsychobiology 2007,55(2),121-122","journal-title":"Neuropsychobiology"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1055\/s-2005-916190","volume":"38","author":"Bickel A.","year":"2005","unstructured":"Bickel A.; Kornhuber J.; Maih\u00f6fner C.; Ropohl A.; Exacerbation of migraine attacks during treatment with the selective serotonin reuptake inhibitor sertraline. A case report. Pharmacopsychiatry 2005,38(6),327-328","journal-title":"Pharmacopsychiatry"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1046\/j.1526-4610.2000.00036.x","volume":"40","author":"Delva N.J.","year":"2000","unstructured":"Delva N.J.; Horgan S.A.; Hawken E.R.; Valproate prophylaxis for migraine induced by selective serotonin reuptake inhibitors. Headache 2000,40(3),248-251","journal-title":"Headache"},{"key":"ref=109","first-page":"235","volume":"54","author":"Larson E.W.","year":"1993","unstructured":"Larson E.W.; Migraine with typical aura associated with fluoxetine therapy: case report. J Clin Psychiatry 1993,54(6),235-236","journal-title":"J Clin Psychiatry"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1097\/00004583-200110000-00005","volume":"40","author":"Munera P.A.","year":"2001","unstructured":"Munera P.A.; Goldstein A.; Migraine and sertraline. J Am Acad Child Adolesc Psychiatry 2001,40(10),1125-1126","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"ref=111","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.12r01464","volume":"15","author":"Mufaddel A.","year":"2013","unstructured":"Mufaddel A.; Osman O.T.; Almugaddam F.; Jafferany M.; A review of body dysmorphic disorder and its presentation in different clinical settings. Prim Care Companion CNS Disord PCC.12r014642013,15(4)","journal-title":"Prim Care Companion CNS Disord"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.comppsych.2009.05.001","volume":"51","author":"Mancuso S.G.","year":"2010","unstructured":"Mancuso S.G.; Knoesen N.P.; Castle D.J.; Delusional versus nondelusional body dysmorphic disorder. Compr Psychiatry 2010,51(2),177-182","journal-title":"Compr Psychiatry"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.beth.2017.01.001","volume":"48","author":"Krebs G.","year":"2017","unstructured":"Krebs G.; Fern\u00e1ndez de la Cruz L.; Monzani B.; Bowyer L.; Anson M.; Cadman J.; Heyman I.; Turner C.; Veale D.; Mataix-Cols D.; Long-term outcomes of cognitive-behavioral therapy for adolescent body dysmorphic disorder. Behav Ther 2017,48(4),462-473","journal-title":"Behav Ther"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1159\/000360740","volume":"83","author":"Veale D.","year":"2014","unstructured":"Veale D.; Anson M.; Miles S.; Pieta M.; Costa A.; Ellison N.; Efficacy of cognitive behaviour therapy versus anxiety management for body dysmorphic disorder: a randomised controlled trial. Psychother Psychosom 2014,83(6),341-353","journal-title":"Psychother Psychosom"},{"key":"ref=115","year":"2013","unstructured":"American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 2013","journal-title":"American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s00213-004-1913-8","volume":"176","author":"New A.S.","year":"2004","unstructured":"New A.S.; Buchsbaum M.S.; Hazlett E.A.; Goodman M.; Koenigsberg H.W.; Lo J.; Iskander L.; Newmark R.; Brand J.; O\u2019Flynn K.; Siever L.J.; Fluoxetine increases relative metabolic rate in prefrontal cortex in impulsive aggression. Psychopharmacology (Berl) 2004,176(3-4),451-458","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1192\/S0007125000291769","author":"Coccaro E.F.","year":"1989","unstructured":"Coccaro E.F.; Central serotonin and impulsive aggression. Br J Psychiatry Suppl 1989(8),52-62","journal-title":"Br J Psychiatry Suppl"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1159\/000362268","volume":"72","author":"Toscano M.","year":"2014","unstructured":"Toscano M.; Vigan\u00f2 A.; Puledda F.; Verzina A.; Rocco A.; Lenzi G.L.; Di Piero V.; Serotonergic correlation with anger and aggressive behavior in acute stroke patients: an intensity dependence of auditory evoked potentials (IDAP) study. Eur Neurol 2014,72(3-4),186-192","journal-title":"Eur Neurol"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S0018-506X(03)00132-6","volume":"44","author":"van der Vegt B.J.","year":"2003","unstructured":"van der Vegt B.J.; Lieuwes N.; Cremers T.I.; de Boer S.F.; Koolhaas J.M.; Cerebrospinal fluid monoamine and metabolite concentrations and aggression in rats. Horm Behav 2003,44(3),199-208","journal-title":"Horm Behav"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/j.1600-0447.1996.tb10654.x","volume":"93","author":"Chong S.A.","year":"1996","unstructured":"Chong S.A.; Low B.L.; Treatment of kleptomania with fluvoxamine. Acta Psychiatr Scand 1996,93(4),314-315","journal-title":"Acta Psychiatr Scand"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"793","DOI":"10.4088\/JCP.v60n1116","volume":"60","author":"Kraus J.E.","year":"1999","unstructured":"Kraus J.E.; Treatment of kleptomania with paroxetine. J Clin Psychiatry 1999,60(11),793","journal-title":"J Clin Psychiatry"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1056\/NEJMcp0801447","volume":"358","author":"Mayer E.A.","year":"2008","unstructured":"Mayer E.A.; Clinical practice. Irritable bowel syndrome. N Engl J Med 2008,358(16),1692-1699","journal-title":"N Engl J Med"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"00223","DOI":"10.1053\/j.gastro.2016.02.032","volume":"S0016-5085","author":"Drossman D.A.","year":"2016","unstructured":"Drossman D.A.; Functional gastrointestinal disorders: history, pathophysiology, clinical features and rome IV. Gastroenterology, 2016,S0016-5085(16),00223-7","journal-title":"Gastroenterology,"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1517\/14740338.2014.902932","volume":"13","author":"Mozaffari S.","year":"2014","unstructured":"Mozaffari S.; Nikfar S.; Abdollahi M.; The safety of novel drugs used to treat irritable bowel syndrome. Expert Opin Drug Saf 2014,13(5),625-638","journal-title":"Expert Opin Drug Saf"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1007\/s10620-019-05600-y","volume":"64","author":"Noorafshan A.","year":"2019","unstructured":"Noorafshan A.; Yousefi M.; Hosseini L.; Karbalay-Doust S.; Can sertraline and nortriptyline protect the neurons in submucosal and myenteric plexuses of Rat\u2019s Colon Against Stress? Dig Dis Sci 2019,64(9),2548-2554","journal-title":"Dig Dis Sci"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s10151-013-1106-8","volume":"18","author":"Stasi C.","year":"2014","unstructured":"Stasi C.; Bellini M.; Bassotti G.; Blandizzi C.; Milani S.; Serotonin receptors and their role in the pathophysiology and therapy of irritable bowel syndrome. Tech Coloproctol 2014,18(7),613-621","journal-title":"Tech Coloproctol"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"3513","DOI":"10.3748\/wjg.v23.i19.3513","volume":"23","author":"Lin W-T.","year":"2017","unstructured":"Lin W-T.; Liao Y.J.; Peng Y.C.; Chang C.H.; Lin C.H.; Yeh H.Z.; Chang C.S.; Relationship between use of selective serotonin reuptake inhibitors and irritable bowel syndrome: A population-based cohort study. World J Gastroenterol 2017,23(19),3513-3521","journal-title":"World J Gastroenterol"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1080\/15622975.2020.1744723","volume":"21","author":"Thibaut F.","year":"2020","unstructured":"Thibaut F.; Cosyns P.; Fedoroff J.P.; Briken P.; Goethals K.; Bradford J.M.W.; The World Federation of Societies of Biological Psychiatry (WFSBP) 2020 guidelines for the pharmacological treatment of paraphilic disorders. World J Biol Psychiatry 2020,21(6),412-490","journal-title":"World J Biol Psychiatry"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.pbb.2013.11.007","volume":"121","author":"Snoeren E.M.S.","year":"2014","unstructured":"Snoeren E.M.S.; Veening J.G.; Olivier B.; Oosting R.S.; Serotonin 1A receptors and sexual behavior in male rats: a review. Pharmacol Biochem Behav 2014,121,102-114","journal-title":"Pharmacol Biochem Behav"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/YCO.0000000000000099","volume":"27","author":"Turner D.","year":"2014","unstructured":"Turner D.; Sch\u00f6ttle D.; Bradford J.; Briken P.; Assessment methods and management of hypersexuality and paraphilic disorders. Curr Opin Psychiatry 2014,27(6),413-422","journal-title":"Curr Opin Psychiatry"},{"key":"ref=131","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jad.2020.11.100","volume":"281","author":"Fontanesi L.","year":"2020","unstructured":"Fontanesi L.; Hypersexuality and Trauma: a mediation and moderation model from psychopathology to problematic sexual behavior. J Affect Disord 2020,281,631-637","journal-title":"J Affect Disord"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.neuropharm.2015.10.034","volume":"102","author":"Bj\u00f6rkholm C.","year":"2016","unstructured":"Bj\u00f6rkholm C.; Monteggia L.M.; BDNF - a key transducer of antidepressant effects. Neuropharmacology 2016,102,72-79","journal-title":"Neuropharmacology"},{"key":"ref=133","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.cell.2021.01.034","volume":"184","author":"Casarotto P.C.","year":"2021","unstructured":"Casarotto P.C.; Antidepressant drugs act by directly binding to TRKB neurotrophin receptors. Cell 2021,184(5),1299-1313","journal-title":"Cell"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1097\/00004714-199606000-00015","volume":"16","author":"Bourgeois J.A.","year":"1996","unstructured":"Bourgeois J.A.; Klein M.; Risperidone and fluoxetine in the treatment of pedophilia with comorbid dysthymia. J Clin Psychopharmacol 1996,16(3),257-258","journal-title":"J Clin Psychopharmacol"},{"key":"ref=135","first-page":"169","volume":"52","author":"Perilstein R.D.","year":"1991","unstructured":"Perilstein R.D.; Lipper S.; Friedman L.J.; Three cases of paraphilias responsive to fluoxetine treatment. J Clin Psychiatry 1991,52(4),169-170","journal-title":"J Clin Psychiatry"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1176\/ajp.147.8.1089c","volume":"147","author":"Bianchi M.D.","year":"1990","unstructured":"Bianchi M.D.; Fluoxetine treatment of exhibitionism. Am J Psychiatry 1990,147(8),1089-1090","journal-title":"Am J Psychiatry"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.pnpbp.2010.04.012","volume":"34","author":"Yang F.W.","year":"2010","unstructured":"Yang F.W.; Liang C.S.; Paraphilias in schizophrenia: differential diagnosis and treatment with selective serotonin reuptake inhibitors. Prog Neuropsychopharmacol Biol Psychiatry 2010,34(6),1126-1127","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=138","first-page":"41","volume":"52","author":"Lorefice L.S.","year":"1991","unstructured":"Lorefice L.S.; Fluoxetine treatment of a fetish. J Clin Psychiatry 1991,52(1),41","journal-title":"J Clin Psychiatry"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1176\/ajp.148.7.950a","volume":"148","author":"Emmanuel N.P.","year":"1991","unstructured":"Emmanuel N.P.; Lydiard R.B.; Ballenger J.C.; Fluoxetine treatment of voyeurism. Am J Psychiatry 1991,148(7),950","journal-title":"Am J Psychiatry"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1258\/msl.2010.010103","volume":"50","author":"Bhatia M.S.","year":"2010","unstructured":"Bhatia M.S.; Jhanjee A.; Srivastava S.; Kumar P.; An uncommon case of hypersexual behaviour with frotteurism. Med Sci Law 2010,50(4),228-229","journal-title":"Med Sci Law"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1097\/00004583-199908000-00008","volume":"38","author":"Aguirre B.","year":"1999","unstructured":"Aguirre B.; Fluoxetine and compulsive sexual behavior. J Am Acad Child Adolesc Psychiatry 1999,38(8),943-943","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1089\/cap.1998.8.195","volume":"8","author":"Galli V.B.","year":"1998","unstructured":"Galli V.B.; Raute N.J.; McConville B.J.; McElroy S.L.; An adolescent male with multiple paraphilias successfully treated with fluoxetine. J Child Adolesc Psychopharmacol 1998,8(3),195-197","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1177\/070674379504000103","volume":"40","author":"Bradford J.M.","year":"1995","unstructured":"Bradford J.M.; Gratzer T.G.; A treatment for impulse control disorders and paraphilia: a case report. Can J Psychiatry 1995,40(1),4-5","journal-title":"Can J Psychiatry"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1023\/A:1014795321404","volume":"31","author":"Chow E.W.C.","year":"2002","unstructured":"Chow E.W.C.; Choy A.L.; Clinical characteristics and treatment response to SSRI in a female pedophile. Arch Sex Behav 2002,31(2),211-215","journal-title":"Arch Sex Behav"},{"key":"ref=145","first-page":"92","volume":"57","author":"Rubenstein E.B.","year":"1996","unstructured":"Rubenstein E.B.; Engel N.L.; Successful treatment of transvestic fetishism with sertraline and lithium. J Clin Psychiatry 1996,57(2),92","journal-title":"J Clin Psychiatry"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"454","DOI":"10.5455\/apd.1414665797","volume":"16","author":"Cetin F.H.","year":"2015","unstructured":"Cetin F.H.; Inappropriate sexual behaviors associated with mental retardation or transvestic fetishism: a case study. Anadolu Psikiyatri Dergisi-Anatolian J Psychiat 2015,16(6),454-457","journal-title":"Anadolu Psikiyatri Dergisi-Anatolian J Psychiat"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1177\/0025802412474813","volume":"53","author":"Patra A.P.","year":"2013","unstructured":"Patra A.P.; Bharadwaj B.; Shaha K.K.; Das S.; Rayamane A.P.; Tripathi C.S.; Impulsive frotteurism: a case report. Med Sci Law 2013,53(4),235-238","journal-title":"Med Sci Law"},{"key":"ref=148","first-page":"278","volume":"18","author":"Ismail N.","year":"2017","unstructured":"Ismail N.; Husain R.; Sidi H.; Anxiety-depression psychopathology of a patient with voyeurism, major depression and premature ejaculation. Asian J Psychiatr 2017,18(2),278-280","journal-title":"Asian J Psychiatr"},{"key":"ref=149","first-page":"86","volume":"55","author":"Zohar J.","year":"1994","unstructured":"Zohar J.; Kaplan Z.; Benjamin J.; Compulsive exhibitionism successfully treated with fluvoxamine: a controlled case study. J Clin Psychiatry 1994,55(3),86-88","journal-title":"J Clin Psychiatry"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1176\/ajp.154.10.1474a","volume":"154","author":"Stewart J.T.","year":"1997","unstructured":"Stewart J.T.; Shin K.J.; Paroxetine treatment of sexual disinhibition in dementia. Am J Psychiatry 1997,154(10),1474","journal-title":"Am J Psychiatry"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1023\/A:1018737504537","volume":"28","author":"Abouesh A.","year":"1999","unstructured":"Abouesh A.; Clayton A.; Compulsive voyeurism and exhibitionism: a clinical response to paroxetine. Arch Sex Behav 1999,28(1),23-30","journal-title":"Arch Sex Behav"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.4088\/JCP.v67n1218","volume":"67","author":"Wainberg M.L.","year":"2006","unstructured":"Wainberg M.L.; Muench F.; Morgenstern J.; Hollander E.; Irwin T.W.; Parsons J.T.; Allen A.; O\u2019Leary A.; A double-blind study of citalopram versus placebo in the treatment of compulsive sexual behaviors in gay and bisexual men. J Clin Psychiatry 2006,67(12),1968-1973","journal-title":"J Clin Psychiatry"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1001\/jama.274.7.535","volume":"274","author":"Haverkos H.W.","year":"1995","unstructured":"Haverkos H.W.; Drotman D.P.; The social organization of sexuality. JAMA 1995,274(7),535-537","journal-title":"JAMA"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.jad.2010.11.010","volume":"131","author":"Mazza M.","year":"2011","unstructured":"Mazza M.; Harnic D.; Catalano V.; Di Nicola M.; Bruschi A.; Bria P.; Daniele A.; Mazza S.; Sexual behavior in women with bipolar disorder. J Affect Disord 2011,131(1-3),364-367","journal-title":"J Affect Disord"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1080\/13554794.2019.1603311","volume":"25","author":"Nordvig A.S.","year":"2019","unstructured":"Nordvig A.S.; Goldberg D.J.; Huey E.D.; Miller B.L.; The cognitive aspects of sexual intimacy in dementia patients: a neurophysiological review. Neurocase 2019,25(1-2),66-74","journal-title":"Neurocase"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"381","DOI":"10.31887\/DCNS.2017.19.4\/dschoettle","volume":"19","author":"Sch\u00f6ttle D.","year":"2017","unstructured":"Sch\u00f6ttle D.; Briken P.; T\u00fcscher O.; Turner D.; Sexuality in autism: hypersexual and paraphilic behavior in women and men with high-functioning autism spectrum disorder. Dialogues Clin Neurosci 2017,19(4),381-393","journal-title":"Dialogues Clin Neurosci"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"11814","DOI":"10.3402\/snp.v2i0.11814","volume":"2","author":"Estellon V.","year":"2012","unstructured":"Estellon V.; Mouras H.; Sexual addiction: insights from psychoanalysis and functional neuroimaging. Socioaffect Neurosci Psychol 2012,2,11814","journal-title":"Socioaffect Neurosci Psychol"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/17482960601073543","volume":"8","author":"Anneser J.M.","year":"2007","unstructured":"Anneser J.M.; Jox R.J.; Borasio G.D.; Inappropriate sexual behaviour in a case of ALS and FTD: successful treatment with sertraline. Amyotroph Lateral Scler 2007,8(3),189-190","journal-title":"Amyotroph Lateral Scler"},{"key":"ref=159","first-page":"311","volume":"49","author":"Herguner S.","year":"2012","unstructured":"Herguner S.; Herguner A.; Cicek E.; Combination of risperidone and paroxetine for inappropriate sexual behaviors in an adolescent with autism and mental retardation. Noropsikiyatri Arsivi-Arch. Neuropsychiatry 2012,49(4),311-313","journal-title":"Neuropsychiatry"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1017\/S1461145705005493","volume":"8","author":"Malladi S.S.","year":"2005","unstructured":"Malladi S.S.; Singh A.N.; Hypersexuality and its response to citalopram in a patient with hypothalamic hamartoma and precocious puberty. Int J Neuropsychopharmacol 2005,8(4),635-636","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.yebeh.2003.10.009","volume":"5","author":"Ozmen M.","year":"2004","unstructured":"Ozmen M.; Erdogan A.; Duvenci S.; Ozyurt E.; Ozkara C.; Excessive masturbation after epilepsy surgery. Epilepsy Behav 2004,5(1),133-136","journal-title":"Epilepsy Behav"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/00004850-200207000-00008","volume":"17","author":"Raymond N.C.","year":"2002","unstructured":"Raymond N.C.; Grant J.E.; Kim S.W.; Coleman E.; Treatment of compulsive sexual behaviour with naltrexone and serotonin reuptake inhibitors: two case studies. Int Clin Psychopharmacol 2002,17(4),201-205","journal-title":"Int Clin Psychopharmacol"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.pnpbp.2007.04.011","volume":"31","author":"Schupak C.","year":"2007","unstructured":"Schupak C.; Case report: lamotrigine\/fluoxetine combination in the treatment of compulsive sexual behavior. Prog Neuropsychopharmacol Biol Psychiatry 2007,31(6),1337-1338","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ajp.2017.10.030","volume":"30","author":"Solanki M.S.","year":"2017","unstructured":"Solanki M.S.; Singh P.; Right thalamic bleed resulting in hypersexuality successfully treated with Selective Serotonin reuptake inhibitor Sertraline - A case report. Asian J Psychiatr 2017,30,210-211","journal-title":"Asian J Psychiatr"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s10072-008-0979-1","volume":"29","author":"Tosto G.","year":"2008","unstructured":"Tosto G.; Talarico G.; Lenzi G.L.; Bruno G.; Effect of citalopram in treating hypersexuality in an Alzheimer\u2019s disease case. Neurol Sci 2008,29(4),269-270","journal-title":"Neurol Sci"},{"key":"ref=166","first-page":"334","volume":"56","author":"Kornreich C.","year":"1995","unstructured":"Kornreich C.; Den Dulk A.; Verbanck P.; Pelc I.; Fluoxetine treatment of compulsive masturbation in a schizophrenic patient. J Clin Psychiatry 1995,56(7),334-334","journal-title":"J Clin Psychiatry"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1176\/ajp.2007.164.5.728","volume":"164","author":"Rao V.","year":"2007","unstructured":"Rao V.; Handel S.; Vaishnavi S.; Keach S.; Robbins B.; Spiro J.; Ward J.; Berlin F.; Psychiatric sequelae of traumatic brain injury: a case report. Am J Psychiatry 2007,164(5),728-735","journal-title":"Am J Psychiatry"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1176\/appi.ajp.158.10.1590","volume":"158","author":"Stein D.J.","year":"2001","unstructured":"Stein D.J.; Black D.W.; Shapira N.A.; Spitzer R.L.; Hypersexual disorder and preoccupation with internet pornography. Am J Psychiatry 2001,158(10),1590-1594","journal-title":"Am J Psychiatry"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/01.mou.0000182327.79572.fd","volume":"15","author":"Jannini E.A.","year":"2005","unstructured":"Jannini E.A.; Lenzi A.; Epidemiology of premature ejaculation. Curr Opin Urol 2005,15(6),399-403","journal-title":"Curr Opin Urol"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.fertnstert.2015.08.035","volume":"104","author":"Jannini E.A.","year":"2015","unstructured":"Jannini E.A.; Ciocca G.; Limoncin E.; Mollaioli D.; Di Sante S.; Gianfrilli D.; Lombardo F.; Lenzi A.; Premature ejaculation: old story, new insights. Fertil Steril 2015,104(5),1061-1073","journal-title":"Fertil Steril"},{"key":"ref=171","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-020-01458-4","author":"Sansone A.","year":"2020","unstructured":"Sansone A.; Management of premature ejaculation: a clinical guideline from the Italian Society of Andrology and Sexual Medicine (SIAMS). J Endocrinol Invest 2020","journal-title":"J Endocrinol Invest"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1111\/j.1743-6109.2010.01975.x","volume":"7","author":"Althof S.E.","year":"2010","unstructured":"Althof S.E.; Abdo C.H.; Dean J.; Hackett G.; McCabe M.; McMahon C.G.; Rosen R.C.; Sadovsky R.; Waldinger M.; Becher E.; Broderick G.A.; Buvat J.; Goldstein I.; El-Meliegy A.I.; Giuliano F.; Hellstrom W.J.; Incrocci L.; Jannini E.A.; Park K.; Parish S.; Porst H.; Rowland D.; Segraves R.; Sharlip I.; Simonelli C.; Tan H.M.; International Society for Sexual Medicine\u2019s guidelines for the diagnosis and treatment of premature ejaculation. J Sex Med 2010,7(9),2947-2969","journal-title":"J Sex Med"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/j.1743-6109.2012.02824.x","volume":"10","author":"McMahon C.G.","year":"2013","unstructured":"McMahon C.G.; Jannini E.; Waldinger M.; Rowland D.; Standard operating procedures in the disorders of orgasm and ejaculation. J Sex Med 2013,10(1),204-229","journal-title":"J Sex Med"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.aju.2013.04.011","volume":"11","author":"Ciocca G.","year":"2013","unstructured":"Ciocca G.; Limoncin E.; Mollaioli D.; Gravina G.L.; Di Sante S.; Carosa E.; Lenzi A.; Jannini E.A.; Integrating psychotherapy and pharmacotherapy in the treatment of premature ejaculation. Arab J Urol 2013,11(3),305-312","journal-title":"Arab J Urol"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1517\/14728220802663549","volume":"13","author":"Abdel-Hamid I.A.","year":"2009","unstructured":"Abdel-Hamid I.A.; Jannini E.A.; Andersson K.E.; Premature ejaculation: focus on therapeutic targets. Expert Opin Ther Targets 2009,13(2),175-193","journal-title":"Expert Opin Ther Targets"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1176\/ajp.151.10.1523a","volume":"151","author":"Forster P.","year":"1994","unstructured":"Forster P.; King J.; Fluoxetine for premature ejaculation. Am J Psychiatry 1994,151(10),1523","journal-title":"Am J Psychiatry"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1097\/00004714-200112000-00003","volume":"21","author":"Waldinger M.D.","year":"2001","unstructured":"Waldinger M.D.; Zwinderman A.H.; Olivier B.; SSRIs and ejaculation: a double-blind, randomized, fixed-dose study with paroxetine and citalopram. J Clin Psychopharmacol 2001,21(6),556-560","journal-title":"J Clin Psychopharmacol"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.12688\/f1000research.12150.1","volume":"6","author":"Kalejaiye O.","year":"2017","unstructured":"Kalejaiye O.; Almekaty K.; Blecher G.; Minhas S.; Premature ejaculation: challenging new and the old concepts. F1000 Res 2017,6,2084","journal-title":"F1000 Res"},{"key":"ref=179","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41585-020-00417-1","volume":"18","author":"Colonnello E.","year":"2021","unstructured":"Colonnello E.; Redefining a sexual medicine paradigm: subclinical premature ejaculation as a new taxonomic entity. Nat Rev Urol 2021,18(2),115-127","journal-title":"Nat Rev Urol"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/0269881117741766","volume":"32","author":"Howes O.D.","year":"2018","unstructured":"Howes O.D.; Rogdaki M.; Findon J.L.; Wichers R.H.; Charman T.; King B.H.; Loth E.; McAlonan G.M.; McCracken J.T.; Parr J.R.; Povey C.; Santosh P.; Wallace S.; Simonoff E.; Murphy D.G.; Autism spectrum disorder: Consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology. J Psychopharmacol 2018,32(1),3-29","journal-title":"J Psychopharmacol"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1016\/S1734-1140(13)71522-6","volume":"65","author":"Mika J.","year":"2013","unstructured":"Mika J.; Zychowska M.; Makuch W.; Rojewska E.; Przewlocka B.; Neuronal and immunological basis of action of antidepressants in chronic pain - clinical and experimental studies. Pharmacol Rep 2013,65(6),1611-1621","journal-title":"Pharmacol Rep"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1155\/2013\/918216","volume":"18","author":"Fitzcharles M.A.","year":"2013","unstructured":"Fitzcharles M.A.; Ste-Marie P.A.; Goldenberg D.L.; Pereira J.X.; Abbey S.; Choini\u00e8re M.; Ko G.; Moulin D.E.; Panopalis P.; Proulx J.; Shir Y.; 2012 Canadian Guidelines for the diagnosis and management of fibromyalgia syndrome: executive summary. Pain Res Manag 2013,18(3),119-126","journal-title":"Pain Res Manag"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"409","DOI":"10.2147\/NSS.S166089","volume":"10","author":"El-Solh A.A.","year":"2018","unstructured":"El-Solh A.A.; Management of nightmares in patients with posttraumatic stress disorder: current perspectives. Nat Sci Sleep 2018,10,409-420","journal-title":"Nat Sci Sleep"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11920-020-01164-1","volume":"22","author":"Stoffers-Winterling J.","year":"2020","unstructured":"Stoffers-Winterling J.; Storeb\u00f8 O.J.; Lieb K.; Pharmacotherapy for borderline personality disorder: an update of published, unpublished and ongoing studies. Curr Psychiatry Rep 2020,22(8),37","journal-title":"Curr Psychiatry Rep"},{"key":"ref=185","first-page":"28","volume":"59","author":"Mayer L.E.","year":"1998","unstructured":"Mayer L.E.; Walsh B.T.; The use of selective serotonin reuptake inhibitors in eating disorders. J Clin Psychiatry 1998,59(Suppl. 15),28-34","journal-title":"J Clin Psychiatry"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.2042-7158.2011.01353.x","volume":"64","author":"Milano W.","year":"2012","unstructured":"Milano W.; De Rosa M.; Milano L.; Capasso A.; Night eating syndrome: an overview. J Pharm Pharmacol 2012,64(1),2-10","journal-title":"J Pharm Pharmacol"},{"key":"ref=187","first-page":"8","volume":"54","author":"Bianciardi E.","year":"2019","unstructured":"Bianciardi E.; Di Lorenzo G.; Niolu C.; Betr\u00f2 S.; Zerbin F.; Gentileschi P.; Siracusano A.; Body image dissatisfaction in individuals with obesity seeking bariatric surgery: exploring the burden of new mediating factors. Riv Psichiatr 2019,54(1),8-17","journal-title":"Riv Psichiatr"},{"key":"ref=188","first-page":"127","volume":"54","author":"Bianciardi E.","year":"2019","unstructured":"Bianciardi E.; Fabbricatore M.; Di Lorenzo G.; Innamorati M.; Tomassini L.; Gentileschi P.; Niolu C.; Siracusano A.; Imperatori C.; Prevalence of Food Addiction and Binge Eating in an Italian sample of bariatric surgery candidates and overweight\/obese patients seeking low-energy-diet therapy. Riv Psichiatr 2019,54(3),127-130","journal-title":"Riv Psichiatr"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s40519-017-0400-2","volume":"22","author":"Vella S.C.","year":"2017","unstructured":"Vella S.C.; Pai N.B.; A narrative review of potential treatment strategies for food addiction. Eat Weight Disord 2017,22(3),387-393","journal-title":"Eat Weight Disord"},{"key":"ref=190","doi-asserted-by":"publisher","first-page":"933","DOI":"10.2147\/TCRM.S262936","volume":"16","author":"Sheikhpour M.","year":"2020","unstructured":"Sheikhpour M.; The current recommended drugs and strategies for the treatment of Coronavirus Disease (COVID-19). Ther Clin Risk Manag 2020,16,933-946","journal-title":"Ther Clin Risk Manag"},{"key":"ref=191","doi-asserted-by":"publisher","first-page":"106044","DOI":"10.1016\/j.ijantimicag.2020.106044","volume":"56","author":"Homolak J.","year":"2020","unstructured":"Homolak J.; Kodvanj I.; Widely available lysosome targeting agents should be considered as potential therapy for COVID-19. Int J Antimicrob Agents 2020,56(2),106044","journal-title":"Int J Antimicrob Agents"},{"key":"ref=192","doi-asserted-by":"publisher","first-page":"972","DOI":"10.4088\/JCP.v67n0615","volume":"67","author":"Chen H.","year":"2006","unstructured":"Chen H.; Reeves J.H.; Fincham J.E.; Kennedy W.K.; Dorfman J.H.; Martin B.C.; Off-label use of antidepressant, anticonvulsant, and antipsychotic medications among Georgia medicaid enrollees in 2001. J Clin Psychiatry 2006,67(6),972-982","journal-title":"J Clin Psychiatry"},{"key":"ref=193","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1592\/phco.28.12.1443","volume":"28","author":"Walton S.M.","year":"2008","unstructured":"Walton S.M.; Schumock G.T.; Lee K.V.; Alexander G.C.; Meltzer D.; Stafford R.S.; Prioritizing future research on off-label prescribing: results of a quantitative evaluation. Pharmacotherapy 2008,28(12),1443-1452","journal-title":"Pharmacotherapy"},{"key":"ref=194","first-page":"498","volume":"68","author":"Stone K.J.","year":"2003","unstructured":"Stone K.J.; Viera A.J.; Parman C.L.; Off-label applications for SSRIs. Am Fam Physician 2003,68(3),498-504","journal-title":"Am Fam Physician"},{"key":"ref=195","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1002\/pds.1825","volume":"18","author":"Chen D.T.","year":"2009","unstructured":"Chen D.T.; Wynia M.K.; Moloney R.M.; Alexander G.C.U.S.; physician knowledge of the FDA-approved indications and evidence base for commonly prescribed drugs: results of a national survey. Pharmacoepidemiol Drug Saf 2009,18(11),1094-1100","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref=196","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1177\/2168479015570337","volume":"49","author":"Ghinea N.","year":"2015","unstructured":"Ghinea N.; Lipworth W.; Kerridge I.; Off-Label promotion of prescription medicine: is it ever justifiable? Ther Innov Regul Sci 2015,49(3),359-363","journal-title":"Ther Innov Regul Sci"},{"key":"ref=197","doi-asserted-by":"publisher","first-page":"101","DOI":"10.4068\/cmj.2018.54.2.101","volume":"54","author":"Wang S.M.","year":"2018","unstructured":"Wang S.M.; Han C.; Bahk W.M.; Lee S.J.; Patkar A.A.; Masand P.S.; Pae C.U.; Addressing the side effects of contemporary antidepressant drugs: a comprehensive review. Chonnam Med J 2018,54(2),101-112","journal-title":"Chonnam Med J"},{"key":"ref=198","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00213-006-0642-6","volume":"191","author":"Goodman W.K.","year":"2007","unstructured":"Goodman W.K.; Murphy T.K.; Storch E.A.; Risk of adverse behavioral effects with pediatric use of antidepressants. Psychopharmacology (Berl) 2007,191(1),87-96","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=199","first-page":"79","volume":"28","author":"Hogg S.","year":"2016","unstructured":"Hogg S.; Ansari S.; Masood Q.; Agius M.; Rihmer Z.; Are SSRIs responsible for precipitating suicidal ideation in teenagers with \u2018subsyndromal\u2019 bipolar affective disorder who have been misdiagnosed with unipolar depression? Psychiatr Danub 2016,28(Suppl. 1),79-82","journal-title":"Psychiatr Danub"},{"key":"ref=200","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.sxmr.2017.07.002","volume":"6","author":"Bala A.","year":"2018","unstructured":"Bala A.; Nguyen H.M.T.; Hellstrom W.J.G.; Post-SSRI sexual dysfunction: a literature review. Sex Med Rev 2018,6(1),29-34","journal-title":"Sex Med Rev"},{"key":"ref=201","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/S0306-4530(01)00097-X","volume":"27","author":"Popova N.K.","year":"2002","unstructured":"Popova N.K.; Amstislavskaya T.G.; Involvement of the 5-HT(1A) and 5-HT(1B) serotonergic receptor subtypes in sexual arousal in male mice. Psychoneuroendocrinology 2002,27(5),609-618","journal-title":"Psychoneuroendocrinology"},{"key":"ref=202","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1472-6920-3-10","volume":"3","author":"Godwin M.","year":"2003","unstructured":"Godwin M.; Seguin R.; Critical appraisal skills of family physicians in Ontario, Canada. BMC Med Educ 2003,3,10","journal-title":"BMC Med Educ"},{"key":"ref=203","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1377\/hlthaff.2010.1024","volume":"30","author":"Mojtabai R.","year":"2011","unstructured":"Mojtabai R.; Olfson M.; Proportion of antidepressants prescribed without a psychiatric diagnosis is growing. Health Aff (Millwood) 2011,30(8),1434-1442","journal-title":"Health Aff (Millwood)"}],"container-title":["Current Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570159X19666210517150418","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/193360\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1570159X19666210517150418","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T01:52:08Z","timestamp":1658281928000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/193360\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":203,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570159x19666210517150418","relation":{},"ISSN":["1570-159X"],"issn-type":[{"value":"1570-159X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-01-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-22","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}